Raleigh Capital Management’s 9 Meters Biopharma NMTR Stock Holding History

Raleigh Capital Management’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2	Closed	-$1	–	1020
2023 Q2	$1	Hold	2	–	–	﹤0.01%	838
2023 Q1	$3	Hold	2	–	–	﹤0.01%	842
2022 Q4	$2	Buy	2 +1	+100%	+$2	﹤0.01%	766
2022 Q3	$0	Hold	1	–	–	﹤0.01%	857
2022 Q2	$0	Hold	1	–	–	﹤0.01%	678
2022 Q1	$0	Buy	+1	New	+$14	﹤0.01%	699

Other funds holding NMTR

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SIS

Strategic Investment Solutions Orland Park, Illinois $437M AUM 30.41% 1-Year Est. Return

RCM

Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

RFA

Raleigh Capital Management's NMTR Position: Q3 2023 in Review

Raleigh Capital Management sold out of 9 Meters Biopharma (NMTR) in Q3 2023, closing a stake of 2 shares — an estimated $1 sold.

Raleigh Capital Management first reported a position in NMTR in Q1 2022 and held it in 6 quarters. The position peaked at $3 in Q1 2023. 6 funds tracked by Wall St. Rank hold NMTR as of Q3 2023.

Raleigh Capital Management reported no remaining 9 Meters Biopharma position as of Q3 2023 after selling out during the quarter.
Raleigh Capital Management sold 2 9 Meters Biopharma shares in Q3 2023, an estimated $1.
Raleigh Capital Management first reported a position in 9 Meters Biopharma in Q1 2022 and held it in 6 quarters.
Raleigh Capital Management's 9 Meters Biopharma position peaked at $3 in Q1 2023.
6 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2023.

Based on Raleigh Capital Management's 13F filing for Q3 2023, filed 6 Dec 2023.